Authorship and contributorship
Comparison of dexmedetomidine and sufentanil for conscious sedation in patients undergoing awake fibreoptic nasotracheal intubation: a prospective, randomised and controlled clinical trial
Article first published online: 1 OCT 2013
© 2013 John Wiley & Sons Ltd
The Clinical Respiratory Journal
Volume 8, Issue 1, pages 100–107, January 2014
How to Cite
Shen, S.-L., Xie, Y.-h., Wang, W.-Y., Hu, S.-F. and Zhang, Y.-L. (2014), Comparison of dexmedetomidine and sufentanil for conscious sedation in patients undergoing awake fibreoptic nasotracheal intubation: a prospective, randomised and controlled clinical trial. The Clinical Respiratory Journal, 8: 100–107. doi: 10.1111/crj.12045
She-Liang Shen is responsible for conception and design, acquisition of data and analysis and interpretation of data. Yi-hong Xie is responsible for conception and design, acquisition of data and critical revision of the manuscript for important intellectual content. Wen-Yuan Wang is responsible for interpretation of data and drafting the manuscript. Yun-Long Zhang is responsible for statistical analysis and supervision. Shuang-Fei Hu is responsible for conception and design and supervision.
Conflict of interest
- Issue published online: 6 JAN 2014
- Article first published online: 1 OCT 2013
- Accepted manuscript online: 1 AUG 2013 02:39AM EST
- Manuscript Accepted: 25 JUL 2013
- Manuscript Revised: 7 MAY 2013
- Manuscript Received: 26 DEC 2012
- awake nasotracheal intubation;
- fibreoptic bronchoscope;
Fibreoptic intubation is a valuable technique for difficult airway management in which conscious sedation is paramount.
To investigate the efficacy and safety of dexmedetomidine (DEX) and sufentanil (SUF) for conscious sedation during awake nasotracheal intubation under vision by a fibreoptic bronchoscope.
Forty patients with anticipated difficult airways of American Society of Anesthesiologists I-II scheduled for awake fibreoptic nasotracheal intubation were randomised into two groups each containing 20 subjects. DEX group received DEX at a dose of 1.0 μg/kg over 10 min followed by a continuous infusion of 0.5 μg/kg per hour, while SUF group received SUF target controlled infusion in which the target plasma concentration was 0.3 ng/mL. The nasotracheal intubation conditions and the tolerance to nasotracheal intubation were observed; the occurrence of adverse events including hypertension, bradycardia and respiratory depression during nasotracheal intubation and post-surgical throat pain and hoarseness, and post-surgical memory score were recorded.
Better nasotracheal intubation conditions and higher tolerance to intubation were observed in DEX group than those in SUF group (P < 0.05). The incidence rates of hypertension, respiratory depression during intubation and throat pain after surgery were lower in DEX group than those in SUF group; however, the incidence of bradycardia was higher in DEX group than that in SUF group.
DEX provides better nasotracheal intubation conditions, improves patients' tolerance to intubation and leads to lower occurrence of hypertension, respiratory depression and throat pain and post-surgical memory score for sedation during awake fibreoptic nasotracheal intubation.